KR20260049875A - 류마티스 관절염의 치료를 위한 조성물 및 방법 - Google Patents

류마티스 관절염의 치료를 위한 조성물 및 방법

Info

Publication number
KR20260049875A
KR20260049875A KR1020267009842A KR20267009842A KR20260049875A KR 20260049875 A KR20260049875 A KR 20260049875A KR 1020267009842 A KR1020267009842 A KR 1020267009842A KR 20267009842 A KR20267009842 A KR 20267009842A KR 20260049875 A KR20260049875 A KR 20260049875A
Authority
KR
South Korea
Prior art keywords
antibody
subject
ser
score
weeks
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020267009842A
Other languages
English (en)
Korean (ko)
Inventor
데보라 바우어
알렉산더 바디
닐 그레이엄
용 린
제니 파리노
라울 파텔
자넷 반 아델스버그
휴버트 반 훅스트라텐
Original Assignee
사노피 바이오테크놀로지
리제너론 파아마슈티컬스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP16305253.3A external-priority patent/EP3216461A1/en
Application filed by 사노피 바이오테크놀로지, 리제너론 파아마슈티컬스, 인크. filed Critical 사노피 바이오테크놀로지
Publication of KR20260049875A publication Critical patent/KR20260049875A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020267009842A 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법 Pending KR20260049875A (ko)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
EP16305253.3 2016-03-07
EP16305253.3A EP3216461A1 (en) 2016-03-07 2016-03-07 Compositions and methods for treating rheumatoid arthritis
EP16170664.3 2016-05-20
EP16170664 2016-05-20
EP16306111.2 2016-09-05
EP16306111 2016-09-05
PCT/US2017/021149 WO2017155990A1 (en) 2016-03-07 2017-03-07 Compositions and methods for treating rheumatoid arthritis
KR1020237019726A KR20230093522A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020237019726A Division KR20230093522A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20260049875A true KR20260049875A (ko) 2026-04-14

Family

ID=58387910

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020267009842A Pending KR20260049875A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법
KR1020187028624A Ceased KR20180114955A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법
KR1020237019726A Ceased KR20230093522A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020187028624A Ceased KR20180114955A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법
KR1020237019726A Ceased KR20230093522A (ko) 2016-03-07 2017-03-07 류마티스 관절염의 치료를 위한 조성물 및 방법

Country Status (18)

Country Link
US (1) US20190100585A1 (https=)
EP (1) EP3426295A1 (https=)
JP (2) JP7166925B2 (https=)
KR (3) KR20260049875A (https=)
CN (1) CN109069642A (https=)
AU (2) AU2017229364A1 (https=)
BR (1) BR112018067851A2 (https=)
CA (1) CA3016880A1 (https=)
CL (1) CL2018002559A1 (https=)
CR (1) CR20180465A (https=)
EA (1) EA201892005A1 (https=)
IL (2) IL261515B2 (https=)
MX (2) MX2018010815A (https=)
PH (1) PH12018501894A1 (https=)
SG (2) SG10202012182YA (https=)
TN (1) TN2018000312A1 (https=)
TW (3) TW202419103A (https=)
WO (1) WO2017155990A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
RU2020121415A (ru) * 2017-11-30 2021-12-30 Био-Тера Солюшнз, Лтд. Жидкий препарат гуманизированного антитела для лечения заболеваний, опосредованных ил-6
SG11202101674QA (en) * 2018-08-29 2021-03-30 Regeneron Pharma Methods and compositions for treating subjects having rheumatoid arthritis
MA54861A (fr) * 2019-01-31 2021-12-08 Regeneron Pharma Anticorps anti-récepteur de l'il6 pour traiter l'arthrite idiopathique juvénile
SG11202111742QA (en) 2019-04-24 2021-11-29 Sanofi Biotechnology Methods of diagnosis and treatment of rheumatoid arthritis
CA3142710A1 (en) * 2019-06-04 2020-12-10 Sanofi Biotechnology Compositions and methods for treating pain in subjects with rheumatoid arthritis
WO2023020563A1 (en) * 2021-08-18 2023-02-23 Bio-Thera Solutions, Ltd. Liquid formulations comprising high concentrations humanized antibodies for treating il-6 related diseases
WO2026047197A1 (en) 2024-08-30 2026-03-05 Sanofi Biotechnology Differential biomarkers for anti-interleukin-6 and anti-tumor necrosis factor-α treatment response in rheumatoid arthritis

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5215534A (en) 1991-12-02 1993-06-01 Lawrence De Harde Safety syringe system
CA2817619A1 (en) * 2001-06-08 2002-12-08 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
JP5307708B2 (ja) 2006-06-02 2013-10-02 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒトｉｌ−６受容体に対する高親和性抗体
GB0718684D0 (en) * 2007-09-24 2007-10-31 Roche Products Ltd Treatment method
JO3417B1 (ar) * 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
US9427531B2 (en) 2010-06-28 2016-08-30 Sanofi-Aventis Deutschland Gmbh Auto-injector
TWI589299B (zh) * 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
US9248242B2 (en) 2012-04-20 2016-02-02 Safety Syringes, Inc. Anti-needle stick safety device for injection device
US20140155827A1 (en) 2012-12-03 2014-06-05 Mylan, Inc. Medicament information system and method
MX377190B (es) * 2013-11-22 2025-03-07 Sanofi Biotechnology Uso de un anticuerpo anti-il6r para el tratamiento de la artritis reumatoide.

Also Published As

Publication number Publication date
CA3016880A1 (en) 2017-09-14
TWI747885B (zh) 2021-12-01
TW201808993A (zh) 2018-03-16
SG10202012182YA (en) 2021-01-28
JP2023011711A (ja) 2023-01-24
JP7745529B2 (ja) 2025-09-29
SG11201807614SA (en) 2018-10-30
TW202419103A (zh) 2024-05-16
MX2023014841A (es) 2024-01-15
WO2017155990A1 (en) 2017-09-14
BR112018067851A2 (pt) 2019-02-05
IL261515B1 (en) 2023-12-01
PH12018501894A1 (en) 2019-05-15
TWI819435B (zh) 2023-10-21
US20190100585A1 (en) 2019-04-04
TW202239767A (zh) 2022-10-16
JP7166925B2 (ja) 2022-11-08
CN109069642A (zh) 2018-12-21
EA201892005A1 (ru) 2019-02-28
EP3426295A1 (en) 2019-01-16
IL261515A (en) 2018-10-31
IL308539A (en) 2024-01-01
CR20180465A (es) 2019-03-04
TN2018000312A1 (en) 2020-01-16
MX2018010815A (es) 2019-01-10
NZ746988A (en) 2023-10-27
IL261515B2 (en) 2024-04-01
KR20230093522A (ko) 2023-06-27
JP2019507775A (ja) 2019-03-22
CL2018002559A1 (es) 2019-03-01
AU2017229364A1 (en) 2018-10-25
KR20180114955A (ko) 2018-10-19
AU2024203011A1 (en) 2024-07-11

Similar Documents

Publication Publication Date Title
JP7745529B2 (ja) 関節リウマチを処置するための組成物及び方法
JP2018512435A (ja) Ｇｄｆ８阻害剤を用いて、強度及び機能を増加させる方法
KR20150048887A (ko) Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
CN114617962A (zh) 使用抗-il-13抗体治疗il-13活性在其中有害的疾病的方法
JP2024161517A (ja) 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
JP7696291B2 (ja) 抗ｉｌ‐１７ａ抗体及びその適用
AU2017366870B2 (en) A pharmaceutical composition for averting opioid addiction
US20230174657A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
CA3108697A1 (en) A pharmaceutical composition for safe and effective treatment of knee and/or hip pain
NZ746988B2 (en) Compositions and methods for treating rheumatoid arthritis
RU2822089C2 (ru) Антитело к рецептору il-6 для лечения ювенильного идиопатического артрита
WO2025166169A1 (en) Compositions, doses, and methods for treatment of c1s mediated diseases and disorders
EP4157872A1 (en) Compositions comprising an antibody against interleukin-6 receptor for the treatment of rheumatoid arthritis and methods of using same
HK40072292A (en) Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies

Legal Events

Date Code Title Description
A16 Divisional, continuation or continuation in part application filed

Free format text: ST27 STATUS EVENT CODE: A-0-1-A10-A16-DIV-PA0104 (AS PROVIDED BY THE NATIONAL OFFICE)

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)